Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma

NCT01616199 is registered in ClinicalTrials.gov with Cascadian Therapeutics Inc. as lead sponsor.

NCT NCT01616199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01616199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma
Lead sponsor
Cascadian Therapeutics Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2012
Completion date
March 31, 2015
Enrollment
24 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced braf-mutant cancers